![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Objectives To collect information on (i) contraceptive methods used immediately before unwanted pregnancy, and (ii) planned contraception following induced abortion among Spanish residents.
Methods Eight centres officially accredited to perform abortions participated in a cross-sectional study. The study population included 2475 women requesting induced abortion between 1 January and 31 March 2007.
Results Contraceptive methods used before unwanted pregnancy were condoms in 40% of the cases, combined hormonal contraception in 14%, and other methods (mainly natural methods and withdrawal) in 10%. Thirty-six percent of women did not use any contraceptive method. Failure of the method due to incorrect use was reported by 77% of those using condoms and by 84% of those using hormonal contraception. Only 23% of women planned to use a contraceptive method after abortion. Almost half of the women were immigrants.
Conclusion Despite the use of effective contraceptive methods, the majority of women requesting induced abortion in Spain became pregnant during the use of these methods. These data reflect a lack of compliance. More education programmes are needed to improve compliance rates. The long-acting reversible contraceptive methods could constitute an appropriate approach.
ACKNOWLEDGEMENTS
We thank the professional staff of the clinics Almozara/Actur in Zaragoza, Belladona in Gijón, Dator, El Bosque and Isadora in Madrid, El Sur in Seville, Mediterránea Médica in Valencia, and Tutor Médica in Barcelona for valuable contribution to the collection of data, and Marta Pulido, MD, for editorial assistance.
Declaration of interest: Isabel Serrano, José Luis Doval, Carme Coll, Javier Martínez-Salmeán, Ezequiel Pérez-Campos and José Luis Dueñas have received fees for speaking from Bayer Schering Pharma. Iñaki Lete has received fees for speaking and reimbursement for attending symposia as opinion leader from Bayer Schering Pharma, MSD, and Janssen Pharmaceutica. Agnés Arbat and Rafael Bermejo are fully employed by Bayer Hispania, Barcelona. The authors alone are responsible for the content and the writing of the paper.